VTRS · Viatris

S&P 500 #391 · Nasdaq

Risiko 6/10 · Generic Pharma Turnaround · $17.86 ▲ 1.28%

Kennzahlen

• Price $17.86
• Market cap $20.8B
• P/E (ttm) n/a
• Div yield 2.72%
• 52-wk range $8.63 – $17.94
• Index rank #391 / —

Wichtigste Risiken

• Generic drug pricing pressure (Biosimilar competition eroding margins) — HIGH
• Negative trailing EPS (-$0.26 TTM) (Profitability recovery not yet confirmed) — HIGH
• Complex global operations post-Pfizer spinoff (Integration and portfolio rationalization) — MED
• Debt reduction pace (Dividend sustainability depends on deleveraging) — MED

Fazit

Global generic and specialty pharma company in a sustained recovery, nearly doubling off its 52-week low.

Interaktive Analyse öffnen → Teilen

Recherche, keine Anlageberatung.